Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Glioblastoma 10Astrocytoma 9Glioma 8Brain Neoplasms 7Oligodendroglioma 6Colorectal Neoplasms 5Urinary Bladder Neoplasms 2Gliosarcoma 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Melanoma 1Lymphoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Digestive System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Doxorubicin 142Ifosfamide 85Radiotherapy 82Cyclophosphamide 72Gemcitabine 63Filgrastim 54pembrolizumab 43pazopanib 40Etoposide 39Docetaxel 39Vincristine 37Trabectedin 37Cisplatin 35Nivolumab 32Magnetic Resonance Spectroscopy 26Irinotecan 26Carboplatin 25Temozolomide 23Surgical Procedures, Operative 23Radiation 22Ipilimumab 22Bevacizumab 20Blood Specimen Collection 19Granulocyte Colony-Stimulating Factor 18Biopsy 18eribulin 17Sirolimus 17Mesna 17Melphalan 17Dactinomycin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Flucytosine × Clear all
NCT02576665 2020-02-07

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Tocagen Inc.

Phase 1 Terminated
21 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Head and Neck Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡